Is Bliss GVS Pharma overvalued or undervalued?

Jun 28 2025 08:01 AM IST
share
Share Via
As of June 27, 2025, Bliss GVS Pharma is fairly valued with a PE ratio of 19.63 and an EV to EBITDA of 12.07, despite a strong 1-year return of 54.05%, especially when compared to peers like Sun Pharma and Cipla.
As of 27 June 2025, the valuation grade for Bliss GVS Pharma has moved from attractive to fair, indicating a reassessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 19.63, an EV to EBITDA of 12.07, and a dividend yield of 0.32%.

When compared to peers, Bliss GVS Pharma's valuation stands out against Sun Pharma, which is considered expensive with a PE ratio of 35.42, and Cipla, which is attractive at a PE of 23.02. Despite a recent strong performance with a 1-year return of 54.05% compared to the Sensex's 6.08%, the overall assessment suggests that Bliss GVS Pharma is fairly valued in the current market landscape.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News